JP2018521641A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018521641A5 JP2018521641A5 JP2017563564A JP2017563564A JP2018521641A5 JP 2018521641 A5 JP2018521641 A5 JP 2018521641A5 JP 2017563564 A JP2017563564 A JP 2017563564A JP 2017563564 A JP2017563564 A JP 2017563564A JP 2018521641 A5 JP2018521641 A5 JP 2018521641A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- peptide
- cancer
- cell
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 57
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 18
- 210000004027 cell Anatomy 0.000 claims description 17
- 238000000338 in vitro Methods 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 7
- 108091007433 antigens Proteins 0.000 claims description 7
- 102000036639 antigens Human genes 0.000 claims description 7
- 230000005847 immunogenicity Effects 0.000 claims description 6
- 238000010186 staining Methods 0.000 claims description 3
- 238000000034 method Methods 0.000 claims 19
- 206010028980 Neoplasm Diseases 0.000 claims 18
- 108020004707 nucleic acids Proteins 0.000 claims 13
- 102000039446 nucleic acids Human genes 0.000 claims 13
- 150000007523 nucleic acids Chemical class 0.000 claims 13
- 210000001519 tissue Anatomy 0.000 claims 13
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims 12
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims 12
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 11
- 239000013604 expression vector Substances 0.000 claims 11
- 108091008874 T cell receptors Proteins 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 239000003446 ligand Substances 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 238000010195 expression analysis Methods 0.000 claims 4
- 230000014509 gene expression Effects 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 3
- 238000003556 assay Methods 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108091023037 Aptamer Proteins 0.000 claims 2
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 2
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 2
- 102000043129 MHC class I family Human genes 0.000 claims 2
- 108091054437 MHC class I family Proteins 0.000 claims 2
- 230000005867 T cell response Effects 0.000 claims 2
- 238000002659 cell therapy Methods 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 230000006698 induction Effects 0.000 claims 2
- 108010028930 invariant chain Proteins 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 238000002493 microarray Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000002018 overexpression Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229920002477 rna polymer Polymers 0.000 claims 2
- 238000012163 sequencing technique Methods 0.000 claims 2
- 238000003860 storage Methods 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 238000011510 Elispot assay Methods 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 108091054438 MHC class II family Proteins 0.000 claims 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 229940022399 cancer vaccine Drugs 0.000 claims 1
- 238000009566 cancer vaccine Methods 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 238000011502 immune monitoring Methods 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004949 mass spectrometry Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229940038309 personalized vaccine Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 238000012070 whole genome sequencing analysis Methods 0.000 claims 1
- 230000000638 stimulation Effects 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 239000011324 bead Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021092252A JP7404306B2 (ja) | 2015-07-01 | 2021-06-01 | 卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2023209805A JP2024037858A (ja) | 2015-07-01 | 2023-12-13 | 卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562187507P | 2015-07-01 | 2015-07-01 | |
| GBGB1511546.2A GB201511546D0 (en) | 2015-07-01 | 2015-07-01 | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| GB1511546.2 | 2015-07-01 | ||
| US62/187,507 | 2015-07-01 | ||
| PCT/EP2016/065166 WO2017001491A2 (en) | 2015-07-01 | 2016-06-29 | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021092252A Division JP7404306B2 (ja) | 2015-07-01 | 2021-06-01 | 卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018521641A JP2018521641A (ja) | 2018-08-09 |
| JP2018521641A5 true JP2018521641A5 (cg-RX-API-DMAC7.html) | 2019-06-13 |
Family
ID=53872514
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017563564A Pending JP2018521641A (ja) | 2015-07-01 | 2016-06-29 | 卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2021092252A Active JP7404306B2 (ja) | 2015-07-01 | 2021-06-01 | 卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021092252A Active JP7404306B2 (ja) | 2015-07-01 | 2021-06-01 | 卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
Country Status (24)
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102224153B (zh) | 2008-09-22 | 2014-04-30 | 阵列生物制药公司 | 作为trk激酶抑制剂的取代的咪唑并[1，2-b]哒嗪化合物 |
| LT3106463T (lt) | 2008-10-22 | 2018-06-25 | Array Biopharma, Inc. | Pakeistieji pirazolo[1,5-]pirimidino junginiai kaip trk kinazės slopikliai |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| PT3205654T (pt) | 2010-05-20 | 2019-04-22 | Array Biopharma Inc | Compostos macrocíclicos como inibidores de cinases trk |
| AU2015346046B2 (en) | 2014-11-16 | 2020-06-25 | Array Biopharma, Inc. | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
| WO2021173560A1 (en) | 2020-02-24 | 2021-09-02 | Immatics US, Inc. | Methods for expanding t cells for the treatment of cancer and related malignancies |
| IL308735A (en) | 2015-07-01 | 2024-01-01 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| US10716544B2 (en) | 2015-10-08 | 2020-07-21 | Zmk Medical Technologies Inc. | System for 3D multi-parametric ultrasound imaging |
| TN2019000271A1 (en) | 2015-10-26 | 2021-01-07 | Univ Colorado Regents | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| GB201520563D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201521746D0 (en) | 2015-12-10 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers |
| EP3389630B1 (en) | 2015-12-16 | 2023-11-08 | Gritstone bio, Inc. | Neoantigen identification, manufacture, and use |
| GB201602918D0 (en) * | 2016-02-19 | 2016-04-06 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
| GB201604490D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides combination of peptides for use in immunotherapy against cancers |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| TN2018000335A1 (en) | 2016-04-04 | 2020-01-16 | Loxo Oncology Inc | Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
| US11261223B2 (en) | 2016-05-11 | 2022-03-01 | The University Of Chicago | Methods of treating cancers with CT45 targeted therapies |
| SI3800189T1 (sl) | 2016-05-18 | 2023-11-30 | Loxo Oncology, Inc. | Priprava (s)-n-(5-((r)-2-(2,5-difluorofenil)pirolidin-1-il)pirazolo (1,5-a)pirimidin-3-il)-3-hidroksipirolidin-1-karboksamida |
| JP7075125B2 (ja) | 2016-05-25 | 2022-05-25 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ |
| GB201609193D0 (en) | 2016-05-25 | 2016-07-06 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
| CN109843327B (zh) | 2016-07-07 | 2022-05-13 | 小利兰·斯坦福大学托管委员会 | 抗体佐剂缀合物 |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| WO2018098715A1 (zh) * | 2016-11-30 | 2018-06-07 | 深圳华大基因研究院 | 多肽及其应用 |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| EP4317432A3 (en) | 2016-12-08 | 2024-04-17 | Immatics Biotechnologies GmbH | T cell receptors with improved pairing |
| CN106636107B (zh) * | 2017-01-20 | 2018-07-31 | 江苏集萃药康生物科技有限公司 | 一种喉癌细胞的核酸适配体及试剂盒 |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| KR20240162609A (ko) * | 2017-04-10 | 2024-11-15 | 이매틱스 바이오테크놀로지스 게엠베하 | 암에 대한 면역요법에 사용하기 위한 펩티드 및 그 조합 |
| KR101970709B1 (ko) | 2017-06-13 | 2019-04-22 | 가톨릭대학교 산학협력단 | ＰＬＫ１ 단백질에 대한 항원―특이 Ｔ 세포 면역반응을 유도하는 ＨＬＡ―Ａ２ 아형―특이 ＰＬＫｌ―유래 항원결정기 |
| US20190016804A1 (en) | 2017-07-14 | 2019-01-17 | Immatics Biotechnologies Gmbh | Dual specificity polypeptide molecule |
| DE102017115966A1 (de) | 2017-07-14 | 2019-01-17 | Immatics Biotechnologies Gmbh | Polypeptidmolekül mit verbesserter zweifacher Spezifität |
| JP2020529437A (ja) * | 2017-08-02 | 2020-10-08 | イーデーペー・ディスカバリー・ファルマ，ソシエダッド・リミターダ | 抗がんペプチド |
| CA3076918A1 (en) * | 2017-10-02 | 2019-04-11 | Curematch, Inc. | Method of prediction of tumor-derived neo-peptide antigenicity and/or immunogenicity using mutational signature patterns |
| JP7227237B2 (ja) | 2017-10-10 | 2023-02-21 | グリットストーン バイオ インコーポレイテッド | ホットスポットを利用した新生抗原の特定 |
| CN111630602A (zh) | 2017-11-22 | 2020-09-04 | 磨石肿瘤生物技术公司 | 减少新抗原的接合表位呈递 |
| DE102017127984B4 (de) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen |
| WO2019112489A1 (en) * | 2017-12-05 | 2019-06-13 | Limited Liability Company "Gero" | Methods and agents for treatment of aging and aging related conditions and diseases |
| EP3746087A4 (en) * | 2018-01-31 | 2022-02-09 | Nx Prenatal Inc. | METHODS FOR EARLY DETECTION AND PREVENTION OF PREECLAMPIA USING CIRCULATION MICROPARTICLE-ASSOCIATED BIOMARKERS |
| AU2019218093A1 (en) | 2018-02-09 | 2020-09-10 | Immatics US, Inc. | Methods for manufacturing T cells |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| TW202016131A (zh) * | 2018-05-16 | 2020-05-01 | 德商英麥提克生物技術股份有限公司 | 用於抗癌免疫治療的肽 |
| CN108939090B (zh) * | 2018-07-13 | 2021-01-01 | 厦门大学 | 一种脂质体、制备方法及用途 |
| TW202019955A (zh) * | 2018-07-31 | 2020-06-01 | 德商英麥提克生物技術股份有限公司 | B*07 限制肽和肽組合的抗癌免疫治療和相關方法 |
| AU2020241686A1 (en) | 2019-03-15 | 2021-11-04 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
| US20200297768A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| PH12021552979A1 (en) | 2019-05-27 | 2023-10-09 | Immatics Us Inc | Viral vectors and their use in adoptive cellular therapy |
| ES2991645T3 (es) | 2019-06-06 | 2024-12-04 | Immatics Biotechnologies Gmbh | Clasificación con contraselección mediante péptidos de secuencia similar |
| WO2020252145A1 (en) * | 2019-06-11 | 2020-12-17 | Iogenetics, Llc | Neoantigen immunotherapies |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| CN112409449B (zh) * | 2019-08-19 | 2023-12-15 | 辽宁中健医药科技有限公司 | Hla-a0201限定性kif15特异性抗肿瘤ctl优势表位肽及应用 |
| US20240082372A1 (en) | 2019-09-02 | 2024-03-14 | Institut Curie | Immunotherapy targeting tumor neoantigenic peptides |
| CN110596386B (zh) * | 2019-09-20 | 2020-06-02 | 四川大学华西医院 | Egflam自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| JP2023518485A (ja) * | 2020-03-23 | 2023-05-01 | コーニンクレッカ フィリップス エヌ ヴェ | 免疫チェックポイント遺伝子に基づく、前立腺がん対象者のための放射線治療応答の予測 |
| WO2021207823A1 (en) * | 2020-04-14 | 2021-10-21 | Université de Montréal | Novel tumor-specific antigens for acute myeloid leukemia (aml) and uses thereof |
| US12295997B2 (en) | 2020-07-06 | 2025-05-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| JP2023533970A (ja) * | 2020-07-08 | 2023-08-07 | マーシー バイオアナリティクス， インコーポレイテッド | 肺癌を検出するための組成物及び方法 |
| WO2022040631A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
| CN112691192B (zh) * | 2020-12-01 | 2022-09-20 | 上海交通大学医学院附属新华医院 | GOLM1在制备负性调控cell-in-cell结构的形成的药物中的应用 |
| US20240016887A1 (en) * | 2020-12-07 | 2024-01-18 | Iogenetics, Llc | Bystander protein vaccines |
| MX2023007817A (es) | 2020-12-31 | 2023-09-13 | Immatics Us Inc | Polipéptidos de cd8, composiciones y métodos de uso de estos. |
| MX2023012899A (es) | 2021-05-05 | 2023-11-08 | Immatics Biotechnologies Gmbh | Polipeptidos de union a antigeno bma031 mejorados. |
| CN113350507B (zh) * | 2021-07-19 | 2022-04-15 | 南通大学 | Cep55作为靶点在制备诊断、预防或治疗结肠炎的药物中的应用 |
| JP2024534825A (ja) | 2021-08-24 | 2024-09-26 | イマティクス ユーエス，アイエヌシー． | 条件付きリガンド交換により産生されたペプチドｍｈｃ複合体を使用する免疫細胞の選択 |
| WO2023044488A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
| US20230192886A1 (en) | 2021-11-08 | 2023-06-22 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
| CN114395625B (zh) * | 2021-12-29 | 2023-08-04 | 广东省人民医院 | Copa在制备子宫颈癌诊断生物标记物和/或子宫颈癌药物开发中的应用 |
| JP2025515603A (ja) | 2022-04-28 | 2025-05-20 | イマティクス ユーエス，アイエヌシー． | Ｉｌ－１２ポリペプチド、ｉｌ－１５ポリペプチド、ｉｌ－１８ポリペプチド、ｃｄ８ポリペプチド、それらの組成物、およびそれらの使用方法 |
| EP4514829A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| WO2023212691A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | DOMINANT NEGATIVE TGFβ RECEPTOR POLYPEPTIDES, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF |
| CN114592006A (zh) * | 2022-04-29 | 2022-06-07 | 昆明理工大学 | Memo1基因的新用途 |
| US20230355678A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
| CN114751961B (zh) * | 2022-06-14 | 2022-09-20 | 中山大学孙逸仙纪念医院 | circ0005199-173aa蛋白及其在制备食管癌诊断产品中的应用 |
| KR20240041396A (ko) * | 2022-09-22 | 2024-04-01 | 차의과학대학교 산학협력단 | 파클리탁셀에 대하여 내성을 갖는 난소암의 진단을 위한 분석방법 |
| CN117074541B (zh) * | 2022-09-23 | 2025-11-25 | 西湖大学 | 预测卵巢癌病人辅助化疗敏感性的蛋白标志物及应用 |
| CN116042825B (zh) * | 2022-09-28 | 2025-07-01 | 南方医科大学 | 一种评估5-fu治疗胃癌癌敏感性的探针引物组及其试剂盒 |
| CN116064806B (zh) * | 2022-10-19 | 2023-09-22 | 常州国药医学检验实验室有限公司 | 一种评估早期胃癌淋巴结转移风险的组合物及其用途 |
| KR20250038870A (ko) * | 2023-09-12 | 2025-03-20 | (주) 수파드엘릭사 | 레티노산 수용체 활성화 펩타이드 및 이를 포함하는 화장료 조성물 |
| WO2025096649A1 (en) | 2023-11-01 | 2025-05-08 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| CN119287020B (zh) * | 2024-12-11 | 2025-03-07 | 湖南宏雅基因技术有限公司 | 一种甲状腺癌甲基化水平检测的引物探针组合物及其应用 |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| BR7908410A (pt) | 1978-12-22 | 1980-09-09 | Biogen Nv | Meio para deteccao de anticorpos de vhb no soro do sangue,e processo para deteccao da presenca da infeccao por virus da hepatite b em seres humanos |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
| US4897445A (en) | 1986-06-27 | 1990-01-30 | The Administrators Of The Tulane Educational Fund | Method for synthesizing a peptide containing a non-peptide bond |
| DE69420137T2 (de) | 1993-06-03 | 1999-12-23 | Therapeutic Antibodies, Inc. | Herstellung von antikörperfragmenten |
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| WO1997026328A1 (en) | 1996-01-17 | 1997-07-24 | Imperial College Innovations Limited | Immunotherapy using cytotoxic t lymphocytes (ctl) |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| TW452771B (en) * | 1998-09-18 | 2001-09-01 | Sony Corp | Reproduction apparatus and reproduction method |
| US20020119158A1 (en) | 1998-12-17 | 2002-08-29 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
| US6858710B2 (en) * | 1998-12-17 | 2005-02-22 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
| WO2001047944A2 (en) | 1999-12-28 | 2001-07-05 | Curagen Corporation | Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
| US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
| CA2404489A1 (en) | 2000-03-27 | 2001-10-04 | Technion Research And Development Foundation Ltd. | Single chain class i major histo-compatibility complexes, constructs encoding same and methods of generating same |
| US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| CN101712721A (zh) | 2000-06-05 | 2010-05-26 | 阿尔托生物科学有限公司 | T细胞受体融合物及共轭物以及其使用方法 |
| AU2002361468A1 (en) * | 2001-08-14 | 2003-03-18 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human S | Method for rapid generation of mature dendritic cells |
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| EP1485075A4 (en) | 2002-02-20 | 2006-04-26 | Dyax Corp | MHC-PEPTIDE COMPLEX BINDING LIGANDS |
| DE10225144A1 (de) | 2002-05-29 | 2003-12-18 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
| AU2003253632A1 (en) | 2002-06-10 | 2003-12-22 | Idec Pharmaceuticals Corporation | Genes overexpressed by ovarian cancer and their use in developing novel therapeutics |
| US7202346B2 (en) | 2002-07-03 | 2007-04-10 | Immunogen Inc. | Antibodies to non-shed Muc1 and Muc16, and uses thereof |
| CA2501870C (en) | 2002-10-09 | 2013-07-02 | Avidex Limited | Single chain recombinant t cell receptors |
| AU2003276403B2 (en) | 2002-11-09 | 2010-04-15 | Adaptimmune Limited | T cell receptor display |
| GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| US7348007B2 (en) * | 2004-02-09 | 2008-03-25 | Ludwig Institute For Cancer Research | Mage C2 antigenic peptides and uses thereof |
| DE102004026135A1 (de) | 2004-05-25 | 2006-01-05 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
| US20110177079A1 (en) | 2004-09-08 | 2011-07-21 | Ludwig Institute For Cancer Research | Cancer-testis antigens |
| US8404803B2 (en) | 2005-03-31 | 2013-03-26 | Chugai Seiyaku Kabushiki Kaisha | Cancer-associated antigen analogue peptides and uses thereof |
| JP4962687B2 (ja) | 2005-08-30 | 2012-06-27 | Ｎｏｋ株式会社 | 密封構造 |
| EP1760089B1 (en) | 2005-09-05 | 2009-08-19 | Immatics Biotechnologies GmbH | Tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules and related anti-cancer vaccine |
| SI1806359T1 (sl) | 2005-09-05 | 2010-06-30 | Immatics Biotechnologies Gmbh | S tumorjem povezani peptidi ki se vežejo brez izjeme na molekule humanega levkocitnega antigena HLA razred II |
| EP2502628B1 (en) | 2006-06-23 | 2016-12-14 | Alethia Biotherapeutics Inc. | Polynucleotides and polypeptide sequences involved in cancer |
| WO2008127285A2 (en) * | 2006-10-05 | 2008-10-23 | The Board Of Trustees Of The University Of Arkansas | Target peptides for ovarian cancer immunotherapy |
| US20100216137A1 (en) | 2007-04-05 | 2010-08-26 | SOURCE PRECISION MEDICINE, INC d/b/a SOURCE MDX | Gene Expression Profiling for Identification, Monitoring and Treatment of Ovarian Cancer |
| PL3042914T3 (pl) | 2007-07-27 | 2019-01-31 | Immatics Biotechnologies Gmbh | Nowe immunogenne epitopy do immunoterapii |
| SI2660248T1 (sl) | 2007-07-27 | 2015-10-30 | Immatics Biotechnologies Gmbh | Nova imunoterapija proti možganskim tumorjem |
| EP2567707B1 (en) | 2007-07-27 | 2016-10-05 | Immatics Biotechnologies GmbH | Composition of tumour-associated peptides and related anti-cancer vaccine |
| JP5580205B2 (ja) | 2007-11-19 | 2014-08-27 | セレラ コーポレーション | 肺癌マーカーとその使用 |
| US20090263574A1 (en) | 2008-04-21 | 2009-10-22 | Quinn Daniel E | Method of restoring an article |
| US20100029748A1 (en) | 2008-08-04 | 2010-02-04 | Sloan-Kettering Institute For Cancer Research | Metastasis Promoting Genes and Proteins |
| PL2172211T3 (pl) | 2008-10-01 | 2015-05-29 | Immatics Biotechnologies Gmbh | Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka |
| WO2010088688A2 (en) | 2009-02-02 | 2010-08-05 | Biotheranostics, Inc. | Diagnosis of in situ and invasive breast cancer |
| CN102348979A (zh) | 2009-03-09 | 2012-02-08 | 乔治亚大学研究基金公司 | 胃癌诊断用蛋白标记的鉴定 |
| GB201004551D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| EP3222632A1 (en) | 2010-03-26 | 2017-09-27 | Memorial Sloan-Kettering Cancer Center | Antibodies to muc16 and methods of use thereof |
| GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| CN103038635B (zh) | 2010-05-11 | 2016-12-28 | 威拉赛特公司 | 用于诊断病状的方法和组合物 |
| GB201009222D0 (en) | 2010-06-02 | 2010-07-21 | Immatics Biotechnologies Gmbh | Improved cancer therapy based on tumour associated antigens derived from cyclin D1 |
| CN102372773B (zh) | 2010-08-11 | 2013-06-05 | 中国科学院生物物理研究所 | 人膀胱癌肿瘤标志物及其抗体和应用 |
| BR112013010213A2 (pt) | 2010-10-26 | 2019-09-24 | Technion Research & Development Foundation Ltd | anticorpos que unem ligantes solúveis de receptores de célula t |
| KR20140044341A (ko) | 2011-06-02 | 2014-04-14 | 알막 다이아그노스틱스 리미티드 | 암에 대한 분자적 진단 검사 |
| CN103782174A (zh) | 2011-06-07 | 2014-05-07 | 卡里斯生命科学卢森堡控股有限责任公司 | 用于癌症的循环生物标志物 |
| EP2771349B1 (en) * | 2011-09-16 | 2020-02-26 | Iogenetics, LLC. | Bioinformatic processes for determination of peptide binding |
| WO2013057586A1 (en) | 2011-10-19 | 2013-04-25 | Oslo Universitetssykehus Hf | Compositions and methods for producing soluble t - cell receptors |
| EP2776451B1 (en) | 2011-11-11 | 2018-07-18 | Fred Hutchinson Cancer Research Center | Cyclin a1-targeted t-cell immunotherapy for cancer |
| GB201201511D0 (en) | 2012-01-30 | 2012-03-14 | Univ Leuven Kath | Modified epitopes for boosting CD4+ T-cell responses |
| WO2014011465A2 (en) * | 2012-07-13 | 2014-01-16 | Albert Einstein College Of Medicine Of Yeshiva University | Aptamer-targeted antigen delivery |
| EP2895864B1 (en) | 2012-09-17 | 2021-03-10 | AIT Austrian Institute of Technology GmbH | Colon cancer diagnostic method and means |
| WO2014071978A1 (en) | 2012-11-08 | 2014-05-15 | Roche Diagnostics Gmbh | Nucleic acids encoding chimeric polypeptides for library screening |
| EP2808392A1 (en) | 2013-05-28 | 2014-12-03 | Rheinische Friedrich-Wilhelms-Universität Bonn | Aptamers and use of the aptamers in the diagnosis and treatment of cancer |
| TWI777198B (zh) | 2013-08-05 | 2022-09-11 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（七） |
| JP6622222B2 (ja) * | 2014-05-28 | 2019-12-18 | ノノ インコーポレイテッド | Ｔａｔ−ＮＲ２Ｂ９ｃの塩化物塩 |
| HK1245401A1 (zh) * | 2014-12-03 | 2018-08-24 | Verik Bio, Inc. | 监定、选择和使用高治疗潜力的t细胞表位 |
| GB201507030D0 (en) | 2015-04-24 | 2015-06-10 | Immatics Biotechnologies Gmbh | Immunotherapy against lung cancers, in particular NSCLC |
| GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
-
2015
- 2015-07-01 GB GBGB1511546.2A patent/GB201511546D0/en not_active Ceased
-
2016
- 2016-06-29 EP EP16733523.1A patent/EP3317296B1/en active Active
- 2016-06-29 PT PT167335231T patent/PT3317296T/pt unknown
- 2016-06-29 CR CR20180001A patent/CR20180001A/es unknown
- 2016-06-29 EA EA201792632A patent/EA201792632A1/ru unknown
- 2016-06-29 SI SI201630998T patent/SI3317296T1/sl unknown
- 2016-06-29 BR BR112017027459A patent/BR112017027459A2/pt not_active Application Discontinuation
- 2016-06-29 EP EP20170129.9A patent/EP3712165A3/en not_active Withdrawn
- 2016-06-29 CA CA2990989A patent/CA2990989A1/en active Pending
- 2016-06-29 MD MDE20180477T patent/MD3317296T2/ro unknown
- 2016-06-29 UA UAA201711177A patent/UA123699C2/uk unknown
- 2016-06-29 RS RS20201506A patent/RS61190B1/sr unknown
- 2016-06-29 MA MA41520A patent/MA41520B2/fr unknown
- 2016-06-29 EA EA201992664A patent/EA201992664A3/ru unknown
- 2016-06-29 HU HUE16733523A patent/HUE052820T2/hu unknown
- 2016-06-29 ES ES16733523T patent/ES2839223T3/es active Active
- 2016-06-29 LT LTEP16733523.1T patent/LT3317296T/lt unknown
- 2016-06-29 WO PCT/EP2016/065166 patent/WO2017001491A2/en not_active Ceased
- 2016-06-29 AU AU2016286274A patent/AU2016286274B2/en not_active Ceased
- 2016-06-29 DK DK16733523.1T patent/DK3317296T3/da active
- 2016-06-29 JP JP2017563564A patent/JP2018521641A/ja active Pending
- 2016-06-29 KR KR1020187003095A patent/KR20180022968A/ko not_active Ceased
- 2016-06-29 MX MX2017017145A patent/MX2017017145A/es unknown
- 2016-06-29 CN CN202110807868.2A patent/CN113480604A/zh active Pending
- 2016-06-29 MA MA050925A patent/MA50925A/fr unknown
- 2016-06-29 SG SG10202001665QA patent/SG10202001665QA/en unknown
- 2016-06-30 US US15/199,270 patent/US10472401B2/en active Active
- 2016-06-30 US US15/199,066 patent/US10253076B2/en active Active
- 2016-06-30 US US15/198,540 patent/US10047131B2/en active Active
- 2016-06-30 US US15/199,182 patent/US10227388B2/en active Active
- 2016-06-30 US US15/198,471 patent/US10000539B2/en active Active
- 2016-06-30 US US15/198,608 patent/US20170037111A1/en not_active Abandoned
- 2016-06-30 US US15/199,244 patent/US10464978B2/en active Active
- 2016-06-30 US US15/199,338 patent/US10738094B2/en active Active
- 2016-06-30 US US15/198,853 patent/US10280205B2/en active Active
- 2016-06-30 US US15/198,620 patent/US20170002055A1/en not_active Abandoned
- 2016-06-30 US US15/199,199 patent/US9908922B2/en active Active
-
2017
- 2017-11-16 US US15/815,644 patent/US20180066032A1/en not_active Abandoned
-
2018
- 2018-05-15 US US15/980,328 patent/US10174089B2/en active Active
- 2018-08-10 US US16/101,081 patent/US10239925B2/en active Active
- 2018-12-06 US US16/212,178 patent/US10494413B2/en active Active
-
2019
- 2019-02-21 US US16/281,790 patent/US10533041B2/en active Active
- 2019-12-13 US US16/713,157 patent/US11485765B2/en active Active
-
2020
- 2020-06-29 US US16/915,745 patent/US10934333B2/en not_active Expired - Fee Related
-
2021
- 2021-01-29 AU AU2021200599A patent/AU2021200599B2/en not_active Ceased
- 2021-05-07 US US17/314,629 patent/US11912748B2/en active Active
- 2021-06-01 JP JP2021092252A patent/JP7404306B2/ja active Active